Summary & Overview

CPT 86153: Pathologist Interpretation of Circulating Tumor Cell Test

CPT code 86153 covers the pathologist’s professional interpretation and reporting of laboratory testing for circulating tumor cells (CTCs). This code captures physician-level diagnostic review distinct from the technical laboratory work. Nationwide, CTC testing and interpretation inform oncology care planning, prognosis assessment, and monitoring of metastatic disease, contributing to precision oncology workflows and potentially affecting treatment decisions.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical service represented by CPT code 86153, how payers typically approach coverage in this space, and what to expect in claims processing for the professional component. The publication also outlines benchmarks and coding context relevant to laboratories and pathology services, summarizes common modifiers used with professional interpretation services, and highlights clinical scenarios where CTC interpretation is applied. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare86153CPTpathologycirculating tumor cellsCTC interpretationlaboratory medicineoncology diagnosticsprofessional componentmedical coding

Billing Code Overview

CPT code 86153 describes the professional interpretation and reporting by a pathologist of a laboratory test for circulating tumor cells (CTCs). The service reflects the physician's analytic review of technical laboratory results and formulation of a diagnostic report and interpretation for clinical teams.

Service type: Pathology interpretation and report generation
Typical site of service: Hospital laboratory, independent clinical laboratory, or pathology department where laboratory testing for circulating tumor cells is performed

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with metastatic breast cancer undergoes serial blood testing to evaluate circulating tumor cells (CTCs) as part of disease monitoring and response assessment. A phlebotomist or nurse collects the peripheral blood specimen and sends it to the clinical laboratory that performs the CTC assay. A pathologist reviews the technical laboratory data, interprets the assay results (including CTC count, morphology, and any immunophenotypic findings), and issues a signed diagnostic report. The report is used by the treating medical oncologist to inform systemic therapy decisions, correlate with imaging, and document disease trajectory. Typical sites of service include an outpatient hospital clinic, hospital laboratory, or independent clinical laboratory where pathology professional interpretation is billed separately from the technical component.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the physician/pathologist interpretation separate from the technical test.
`TC`	Technical component	Use when billing only the laboratory technical portion (if facility bills separately).
`90`	Reference (outside) laboratory	Use when the test is performed by an outside reference laboratory and only results are reported.
`52`	Reduced services	Use when the physician provides a reduced level of interpretive service compared with full service.
`53`	Discontinued procedure	Use if the specimen could not be adequately obtained or test discontinued for patient safety reasons.
`59`	Distinct procedural service (not in provided raw list)	Data not available in the input.
`62`	Two surgeons — unlikely for this code but available	Use when two physicians share substantive participation in the interpretation (rare for path).
`80`	Assistant surgeon	Use when an assistant participates in the procedure requiring billing (rarely applicable).
`82`	Assistant surgeon (no qualified resident)	Similar limited use; typically not applicable to interpretive pathology codes.
`22`	Increased procedural services	Use when the interpretation required substantially greater work than typical and documentation supports a modifier 22.
`23`	Unusual anesthesia — not typical for this service	Use only if unusual anesthesia affects reporting (rare for blood-based assays).
`90`	Reference (outside) laboratory	(duplicate entry in raw list; see above)
`QX`	Ordering physician attests to qualified non-physician	Use when a non-physician practitioner performs a portion of the service under supervision and attestation is required.
`QK`	Medical direction of two or more qualified individuals	Use when applicable to supervision/medical direction arrangements.

Taxonomy Code	Specialty	Notes
207RM0500X	Anatomic and Clinical Pathology	Pathologists performing interpretation and reporting of CTC assays.
2080P0204X	Hematology	Hematopathologists involved when blood-based tumor cell identification overlaps with hematologic evaluation.
207RH0000X	Clinical Pathology	Laboratory directors who oversee assay validation and reporting.
2080S0120X	Medical Oncology	Ordering and utilizing CTC results for therapeutic decision-making.
207RR0500X	Anatomic Pathology	Pathologists who correlate morphologic findings with CTC assay results.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C50.912`	Malignant neoplasm of unspecified site of right female breast, upper-inner quadrant	Breast cancer is commonly monitored with CTC assays for metastatic disease and treatment response.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Metastatic disease such as liver metastases prompts CTC testing to assess tumor burden and dissemination.
`C79.51`	Secondary malignant neoplasm of bone	Bone metastases are a clinical scenario where CTC counts can correlate with progression.
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Lung cancer patients may have CTC testing for staging or surveillance.
`C61`	Malignant neoplasm of prostate	Prostate cancer can be evaluated with CTC assays in advanced disease for prognosis and therapy monitoring.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`86304`	Immunoassay for tumor associated antigen(s), qualitative or semi-quantitative, each	May be used for adjunctive tumor marker testing that complements CTC interpretation.
`88360`	Immunohistochemistry, per specimen; initial single antibody stain	Used when additional immunophenotypic stains are performed on circulating cell preparations or correlated tissue.
`88175`	Cytopathology, cell block, each ancillary interpretation	May be used if a cell block is prepared from blood specimen for further morphologic or immunostain evaluation.
`CPT code not provided`	Data not available in the input.	Data not available in the input.